uniQure N.V. Proceeds from Maturities, Prepayments and Calls of Held-to-maturity Securities
uniQure N.V. (QURE) reported Proceeds from Maturities, Prepayments and Calls of Held-to-maturity Securities of $98.70 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities · last filed 2026-05-05
- uniQure N.V. proceeds from maturities, prepayments and calls of held-to-maturity securities for the quarter ending 2026-03-31 was $98.70M, a 16.12% increase year-over-year.
- uniQure N.V. proceeds from maturities, prepayments and calls of held-to-maturity securities for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- uniQure N.V. proceeds from maturities, prepayments and calls of held-to-maturity securities for the quarter ending 2025-09-30 was $123.43M, a 32.55% decline year-over-year.
- uniQure N.V. proceeds from maturities, prepayments and calls of held-to-maturity securities for the quarter ending 2025-06-30 was $128.76M, a 12.82% decline year-over-year.
- uniQure N.V. proceeds from maturities, prepayments and calls of held-to-maturity securities for fiscal 2025 was $337.19M, a 36.91% decline from fiscal 2024.
- uniQure N.V. proceeds from maturities, prepayments and calls of held-to-maturity securities for fiscal 2024 was $534.50M, a 218.33% increase from fiscal 2023.
- uniQure N.V. proceeds from maturities, prepayments and calls of held-to-maturity securities for fiscal 2023 was $167.91M.
| Period end | Proceeds from Maturities, Prepayments and Calls of Held-to-maturity Securities 3 month | Proceeds from Maturities, Prepayments and Calls of Held-to-maturity Securities 6 month | Proceeds from Maturities, Prepayments and Calls of Held-to-maturity Securities 9 month | Proceeds from Maturities, Prepayments and Calls of Held-to-maturity Securities 12 month |
|---|---|---|---|---|
| 2026-03-31 | $98.70M 10-Q · filed 2026-05-05 | $98.70M derived: sum of 2 quarters · filed 2026-05-05 | $222.13M derived: sum of 3 quarters · filed 2026-05-05 | $350.89M derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $123.43M derived: sum of 2 quarters · filed 2026-03-02 | $252.19M derived: sum of 3 quarters · filed 2026-03-02 | $337.19M 10-K · filed 2026-03-02 |
| 2025-09-30 | $123.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $252.19M derived: sum of 2 quarters · filed 2025-11-10 | $337.19M 10-Q · filed 2025-11-10 | $390.89M derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-06-30 | $128.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-29 | $213.76M 10-Q · filed 2025-07-29 | $267.45M derived: sum of 3 quarters · filed 2026-05-05 | $450.45M derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-03-31 | $85.00M 10-Q · filed 2026-05-05 | $138.69M derived: sum of 2 quarters · filed 2026-05-05 | $321.69M derived: sum of 3 quarters · filed 2026-05-05 | $469.39M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $53.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $236.69M derived: sum of 2 quarters · filed 2026-03-02 | $384.39M derived: sum of 3 quarters · filed 2026-03-02 | $534.50M 10-K · filed 2026-03-02 |
| 2024-09-30 | $183.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $330.70M derived: sum of 2 quarters · filed 2025-11-10 | $480.81M 10-Q · filed 2025-11-10 | $542.41M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $147.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-29 | $297.81M 10-Q · filed 2025-07-29 | $359.41M derived: sum of 3 quarters · filed 2026-03-02 | $413.48M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $150.11M 10-Q · filed 2025-05-09 | $211.71M derived: sum of 2 quarters · filed 2026-03-02 | $265.78M derived: sum of 3 quarters · filed 2026-03-02 | $312.68M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $61.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $115.67M derived: sum of 2 quarters · filed 2026-03-02 | $162.58M derived: sum of 3 quarters · filed 2026-03-02 | $167.91M 10-K · filed 2026-03-02 |
| 2023-09-30 | $54.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $100.98M derived: sum of 2 quarters · filed 2024-11-05 | $106.31M 10-Q · filed 2024-11-05 | |
| 2023-06-30 | $46.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $52.23M 10-Q · filed 2024-08-01 | ||
| 2023-03-31 | $5.33M 10-Q · filed 2024-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |